This segment focuses on the development, manufacturing, and commercialization of finished drug products across a range of therapeutic areas. CSPC's R&D efforts in this segment are geared towards creating innovative formulations and improving existing drug delivery systems. Technologies employed include advanced pharmaceutical manufacturing processes and formulation techniques. The therapeutic areas covered include neurology (NBP soft capsules and injections, Oulaining), cardiovascular diseases (Xuanning), oncology (Duomeisu, Keaili), and infectious diseases (Shuluoke, Nuomoling, Weihong, Xinweihong). These drugs aim to improve patient outcomes by providing effective treatments for critical conditions. CSPC maintains a strong market position through continuous innovation and strategic partnerships, focusing on expanding its product portfolio and market reach. Regulatory compliance and clinical validation are crucial aspects of this segment, ensuring the safety and efficacy of the drugs.

CSPC's oncology segment is dedicated to the research and development of innovative therapies for various types of cancer. This includes developing treatments for lymphoma, multiple myeloma, ovarian cancer, and breast cancer (Duomeisu, Keaili). The company invests heavily in R&D to discover novel drug candidates and improve existing treatments. Technologies used in this segment include molecular biology, biochemistry, and advanced drug delivery systems. The focus is on developing targeted therapies that can improve patient outcomes and reduce side effects. CSPC's oncology pipeline includes both small molecule drugs and biologics, with a strong emphasis on precision medicine. Clinical trials are a critical part of this segment, ensuring the safety and efficacy of new treatments. The company aims to address unmet medical needs in oncology and provide patients with access to cutting-edge therapies.

This segment is dedicated to developing treatments for conditions affecting the heart and brain, including acute ischemic stroke, hypertension, and atherosclerotic thrombosis events (NBP, Xuanning, Encun). CSPC focuses on innovative drug development and improving existing therapies to enhance patient outcomes. Research and development activities include identifying novel drug targets and developing advanced drug delivery systems. Technologies used in this segment include molecular biology, pharmacology, and clinical research. The company aims to address unmet medical needs in cardiovascular and cerebrovascular diseases, providing effective treatments to improve the quality of life for patients. Clinical trials and regulatory compliance are essential to ensure the safety and efficacy of new therapies. CSPC's market positioning is strengthened by strategic partnerships and a commitment to innovation.